新生儿患有耐火性急性肺高血压的血管压素
Simon Ouellet1, Christine Drolet1,2, Geneviève Morissette1,3
1Department of Pediatrics, CHU de Québec, Université Laval, Quebec City, Canada.
Pediatric research
|January 11, 2024
概括
血管压素在治疗急性肺高血压 (aPH) 的新生儿中表现有前途,这些新生儿对其他疗法不耐药. 这种治疗改善了氧化和血液动力状况,尽管观察到低血症.
科学领域:
- 新生儿医学 新生儿医学
- 儿童心脏病学 儿童心脏病学
- 关键的护理关键的护理
背景情况:
- 新生儿急性肺高血压 (aPH) 是一种严重的疾病,治疗选择有限.
- 耐火性aPH在新生儿重症监护中带来了重大管理挑战.
研究的目的:
- 评估瓦索普林素作为新生儿耐火性aPH的辅助疗法的疗效和安全性.
- 评估压素对这种患者群体中氧化和血液动力学参数的影响.
主要方法:
- 回顾性单中心队列研究.
- 包括新生儿 (<1个月) 用压素治疗耐火性aPH (2016-2022年).
- 分析了氧化指数,氧气需求和平均动脉压的变化.
主要成果:
- 压素的使用导致氧化指数显著改善 (28.4~14.4,p=0.004).
- 减少氧气需求 (FiO2从0.91到0.50,p=0.004) 和增加平均动脉压 (41到51 mmHg,p=0.001).
- 低血症发生在接受压素的68%的患者中.
结论:
- 血管压素可以改善新生儿aPH耐初始治疗的氧化和血液动力学.
- 需要进一步的前性研究来确认安全性,特别是在早产婴儿中.
- 压素是新生儿aPH的潜在心脏otropic 药物,需要仔细的监测.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
166
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
216
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
216
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
183
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183
Acute Respiratory Failure-V
141
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
141
Mechanical Ventilation III: Noninvasive Ventilation
123
Noninvasive positive-pressure ventilation (NIPPV), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP) are essential methods in respiratory care. These ventilation techniques offer unique benefits for patients with various respiratory conditions, providing adequate support without requiring intubation. Let's explore how each method is crucial in improving patient outcomes and enhancing respiratory therapy.
Noninvasive Positive-Pressure Ventilation...
Noninvasive Positive-Pressure Ventilation...
123


